药明生物：截至二零二四年十二月三十一日止之全年业绩公告

*WUXIBIOLOGICS (CAYMAN) INC. 2269 CRDMO 15181766212013 (1)(2)510(3)CMO(4) 9.6%18,675.413.1%12.1%7,650.810.5%3,945.41851058037MSDInternational GmbHMSD International30 CRDMO CRDMO—(R) GBR800CRDMORGBRCROFIPINDCMC 15070WuXiBodyTMmAbWuXiBodyTM50 VHHVHHVHHVHHSDArBodYTMWuXiBodyTMSDArBodYTM TTCEICECD3 mAbTCETCETCEγδTCENK(NKCE)ICE TAAmAbTAATAAmAbADC BBerkeley Light BeaconB GSK plcGSKTCECandid Therapeutics, Inc.WuXiBodyTMTCEBioNTech SEBNTXmAbMedigene AGMDG1T(TCR)TCE(TCR-TCEs)FIPAadi Bioscience,Inc.AADIADC(R) CRDMO—(D) mAbDNAIND600IND WuXiaTMCHOWuXiaTM150CMC1,000WuXia RidGSTMWuXiaTMGSCHOWuXiaADCCPLUSTMADCCWuXia RidGSTMWuXiaADCCPLUSTMWuXiaTM WuXiUPTMWuXiUPTMWuXiUPTM1,0002,00010,00020,000WuXiUPTM1402010010IND WuXiUITMWuXiUITM(UI-IPFB)35mAb36WuXiUITM2,000GMP WuXiHighTM≥100WuXiHighTMWuXiHighTM100230 BCN201Merck & Co., Inc.MRKCRDMOCN201WuXiBody™TCEWuXiUP™ CRDMO—(M) cGMP2005,000 662113 PPQ98%16PPQ HPRAGMP16,000PPQ CMCGMP(VLP)pDNAEffiXTM ADCCRDMO2268194ADCiCMCCMC34II TCECRDMO—(R)TCE 4222EMAFDA1,500GMP200QP ESGESG SBTiUNGCPSCIESG 5,000GMP23,000DP17GMP MFG6MFG6.2EMPQ —MFG11MFG11MFG1166,000 MFG18 WBS WBS260ESGWBS ESGCDMOIMAPACCDMOCMO(The Life Science Industry Awards 2024)sHeroESGMSCIESGAAAEcoVadisSustainalyticsESGCDPAA-ESGUNGCMSCI ESGESG 50 CRDMO ADC CRDMO CRDMOWBS 17,034.39.6%18,675.4(i)(ii)ADCs(iii)(iv) IND30.7%7,062.237.8%III3,815.55.5%20.4%III3.2%7,485.0 40.1%3.9% INDIIIIII 6,059.710.2%5,442.329.1%35.6% 7,660.41.7%7,787.741.7%45.0% XDCXDCADCsCRDMO 10,206.48.0%11,024.6 6,827.912.1%7,650.840.1%41.0%WBS 416.741.1%588.1 320.0151.8(i)(ii)(iii) 181.636.5(i)(ii) 294.061.1%473.61.7%2.5% 1,495.411.9%1,673.5(i)(ii) 785.82.5%766.4WBS 157.6158.5 603.247.4%889.023.6%21.4% 3,570.610.5%3,945.421.1%21.0% 3,399.71.3%3,356.120.0%18.0% 0.820.771.3%0.78 27,377.64.8%26,070.5 2,561.87.7%2,364.9 1,529.9 511.813.6%442.4 1,393.59.1%1,266.6 1,519.325.4%1,133.3 1,233.657.6%523.6 1,765.813.8%1,521.7WBS 1,223.722.0%1,492.9 6,292.70.8%6,240.7 499.761.6%191.9 MSD International 2,755.80.8%2,778.2(i)MSD InternationalMSD International(ii) 3,089.823.8%2,355.8 711.279.9%142.8MSD International 2,414.04.6%2,303.6 10,186.210,009.8(i)(ii)(iii) 2,147.422.8%2,636.2 710.41.4%3.9%1,358.65.6%6.5%567.22.4%6.0% 2,435.331.594.674.8 18.022.8%13.9 16.948.3 100%4.9%5.8% —1.171.13—1.121.06 a)b)c)d) 12,5754,38395.8%(i)(ii)5,073.34,486.6 1617 C1F.2.2 118,000,000112.00111.20120.40 10,899.0(i)40%(DS/DP)(ii)40%(iii)10%mRNA(iv)10% 125,512,5001,938.09 • • ••• WuXi VaccinesIreland LimitedMSD InternationalWuXi Vaccines IrelandLimitedMSD International (www.hkexnews.hk)(www.wuxibiologics.com) 3,356,0813,399,729589,290170,895 3,945,3713,570,624 2,524,6603,190,997591,991186,555 3,116,6513,377,552 16 1. CRDMO 2. 161177 97397310281—113212184 1234 3. 4. CRDMO 5. ———— 7,600,712,0003,593,255,0002,392,077,0001,717,993,00011,145,776,0003,477,556,0002,139,451,000485,456,000 10% 2,064,9541,937,363 AB 10% 6. i.ii. 7. 8. 6.34%6.45%1.27%6.46% 9. ——— 10. ——— 25% 28.25%216.5% 15% 11. 4,227,164,5674,348,874,478 67,478,24476,792,800 12. —— —— 1090 — 90— 911— 1 1,736,864,0001,945,607,000899,294,0001,107,602,00090 14. —— 15. 0%4.50%0%5.68% 2.60%5.76%1.7%2.8% 16. WuXi Vaccines Ireland LimitedMSD International GmbHMSDInternational —— —— 90 19. 506,30057,5002,129,9002,089,8742,636,2002,147,374 1.5%0.75%0.8%0.79%50.9%10.7% —— 16,930,00010,299,000 20. ADC ADCC CDMO(Contract Development andManufacturing Organization) C1 cGMP CMC(Chemical Manufacturing andControl) CMO(Contract Manufacturing Organization) WuXi Biologics (Cayman) Inc.* CRDMO(Contract Research,Development and Manufacturing Organization) CRO(Contract Research Organization) DNA GMP(Good Manufacturing Practice) C3 mRNA PPQ — E. 1/120,000 WuXi Biologics (Cayman) Inc.* William Robert KellerKenneth WaltonHitchner III *